thymosin alpha 1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-04-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual description varies by batch |
| Solubility | Freely soluble in water | Aqueous buffers are commonly used |
| Typical storage temperature | -20 °C or below for powder | Reconstituted liquid kept at 2-8 °C short term |
| Purity method | Reversed-phase HPLC | Value derived from peak area integration |
| Identity method | Mass spectrometry | Confirms mass and sequence integrity |
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
The classic symptom of keratoconus is the perception of multiple "ghost" images, known as monocular polyopia. This effect is most clearly seen with a high contrast field, such as a point of light on a dark background. Instead of seeing just one point, a person with keratoconus sees many images of the point, spread out in a chaotic pattern. This pattern does not typically change from day to day, but over time, it often takes on new forms. People also commonly notice streaking and flaring distortion around light sources. Some even notice the images moving relative to one another in time with their heartbeat. The predominant optical aberration of the eye in keratoconus is coma. The visual distortion experienced by the person comes from two sources, one being the irregular deformation of the surface of the cornea, and the other being scarring that occurs on its exposed highpoints. These factors act to form regions on the cornea that map an image to different locations on the retina. The effect can worsen in low light conditions, as the dark-adapted pupil dilates to expose more of the irregular surface of the cornea. Significant retinal layer thickness reduction is observed in keratoconus, especially in younger patients (<30 years).
== Pathophysiology == Acanthosis nigricans results from activation of growth factor receptor pathways, most commonly insulin-mediated stimulation of insulin-like growth factor receptor on keratinocytes and fibroblasts. Hyperinsulinaemia may also displace IGF-1 from its binding proteins, amplifying epidermal proliferation. Contributing mechanisms include:
The male is slender, and the blue line is straighter. The female is rounder, producing a bent blue line. Some aquarists say the females look plumper when viewed from above. However, the straightness of the line and the plumpness of the female might occasionally be due to the eggs she is carrying. A neon tetra can appear slightly plump in the belly due to having overeaten. Neon tetras need dim lighting, a DH less than one, about 5.5 pH, and a temperature of 75 °F (24 °C) to breed. There also needs to be a lot of tannins in the water. Neon tetras are old enough to breed at 12 weeks. Breeding neon tetras is considered to be difficult in home aquariums. However, it is becoming more common, with less than 5% of specimens currently sold in America caught in the wild, and more than 1.5 million specimens imported to America each month from fish farms.
Sources: en.wikipedia.org
=== Metals === The biological half-life of caesium in humans is between one and four months. This can be shortened by feeding the person prussian blue. The prussian blue in the digestive system acts as a solid ion exchanger which absorbs the caesium while releasing potassium ions. For some substances, it is important to think of the human or animal body as being made up of several parts, each with its own affinity for the substance, and each part with a different biological half-life (physiologically-based pharmacokinetic modelling). Attempts to remove a substance from the whole organism may have the effect of increasing the burden present in one part of the organism. For instance, if a person who is contaminated with lead is given EDTA in a chelation therapy, then while the rate at which lead is lost from the body will be increased, the lead within the body tends to relocate into the brain where it can do the most harm.
=== Asia === Inter University Accelerator Centre (IUAC), New Delhi 110067 . Xi'an AMS Center, China Tandem accelerator for Environmental Research and Radiocarbon Analysis (NIES-TERRA) of the National Institute for Environmental Studies (NIES), Tsukuba, Japan BINP AMS Facility, Novosibirsk, Russia National Taiwan University, Department of Geosciences, Taipei, Taiwan Accelerator Unit for Radio isotope Studies (AURiS), Geoscience Division, Physical Research Laboratory, Ahmedabad, India. China Institute for Radiation Protection, Taiyuan, China Laboratory of AMS Dating and the Environment, Nanjing University, China
== History == EcPLA was first described in the scientific literature by a team that included Adam Halberstadt, Alexander Stratford, Jason Wallach, and David E. Nichols in 2019. It was developed by Lizard Labs. The drug was encountered online as a novel designer drug in around 2020 and became more widely available in early 2022.
Sources: en.wikipedia.org
=== Classification by staining === The Gram stain, developed in 1884 by Hans Christian Gram, characterises bacteria based on the structural characteristics of their cell walls. The thick layers of peptidoglycan in the "Gram-positive" cell wall stain purple, while the thin "Gram-negative" cell wall appears pink. By combining morphology and Gram-staining, most bacteria can be classified as belonging to one of four groups (Gram-positive cocci, Gram-positive bacilli, Gram-negative cocci and Gram-negative bacilli). Some organisms are best identified by stains other than the Gram stain, particularly mycobacteria or Nocardia, which show acid fastness on Ziehl–Neelsen or similar stains.
In contrast to early inefficient dry- packing methods, wet slurry packing, in which particles that are suspended in an appropriate solvent are delivered into a column under pressure, shows significant improvement. Three different approaches can be employed in performing wet slurry packing: the balanced density method (solvent's density is about that of porous silica particles), the high viscosity method (a solvent of high viscosity is used), and the low viscosity slurry method (performed with low viscosity solvents). Polystyrene is used as a medium for ion-exchange. It is made from the polymerization of styrene with the use of divinylbenzene and benzoyl peroxide. Such exchangers form hydrophobic interactions with proteins which can be irreversible. Due to this property, polystyrene ion exchangers are not suitable for protein separation. They are used on the other hand for the separation of small molecules in amino acid separation and removal of salt from water. Polystyrene ion exchangers with large pores can be used for the separation of protein but must be coated with a hydrophilic substance. Cellulose based medium can be used for the separation of large molecules because they contain large pores. Protein binding in this medium is high and has low hydrophobic character. DEAE is an anion exchange matrix that is produced from a positive side group of diethylaminoethyl bound to cellulose or Sephadex. Agarose gel based medium contain large pores as well but their substitution ability is lower in comparison to dextrans.
A gel refers to the semi-solid, 3-dimensional matrix formed from an interspersed system of colloidal particles or the permeation of a solvent into an entwined polymer chain network. Pharmaceutical gels are formed by adding a gelator (gelling agent) to the solvent and active ingredient mixture. Gelators used in gel formulation can be small molecules with low molecular weight or polymers (synthetic, semi-synthetic or natural). The solvent that is used as a dispersion medium can be aqueous, organic, inorganic, or a system of different solvents. Topical gels are used as a contact or transport medium for active drugs to act on or through the skin. The active drug molecules are entwined into the 3D mesh of the gel and delivered to the site of action.
Sources: en.wikipedia.org
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.
Mass spectrometry is the standard confirmation of molecular mass and acetylation state. Chromatography establishes purity but does not identify the molecule on its own. The two techniques are normally applied together during verification.
No, because the reported value reflects the detection method and wavelength used, which vary between laboratories. A number stated without method details cannot be compared directly with another supplier's figure. Requesting the chromatogram and the method conditions is a common way to interpret it.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.